Carlos Traynor

Mr. Carlos Traynor

AstraZeneca
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MJMartin Johnson
Martin Johnson
CTCarlos Traynor
Carlos Traynor
KVKarthick Vishwanathan
Karthick Vishwanathan
POPhilip Overend
Philip Overend
RHRyan Hartmaier
Ryan Hartmaier
SRSuresh S. Ramalingam
Suresh S. Ramalingam

13 December 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
CTCarlos Traynor
Carlos Traynor
TSTarjinder Sahota
Tarjinder Sahota
HTHelen Tomkinson
Helen Tomkinson
IGIgnacio Gonzalez-Garcia
Ignacio Gonzalez-Garcia
NENeil Evans
Neil Evans
MCMichael Chappell
Michael Chappell
Missing data is a universal problem in analysing Real-World Evidence (RWE) datasets. In RWE datasets, there is a need to understand which features best correlate with clinical outcomes. In this context, the missing status of several biomarkers may appear as gaps in the dataset that hide meaningful values for analysis. Imputation methods are general strategies that replace missing values with plausible values. Using the Flatiron NSCLC dataset, including more than 35,000 subjects, we compare the imputation performance of six such methods on missing data: predictive mean matching, expectation-maximisation, factorial analysis, random forest, generative adversarial networks and multivariate imputations with tabular networks. We also conduct extensive synthetic data experiments with structural causal models. Statistical learning from incomplete datasets should select an appropriate imputation algorithm accounting for the nature of missingness, the impact of missing data, and the distribution shift induced by the imputation algorithm. For our synthetic data experiments, tabular networks had the best overall performance. Methods using neural networks are promising for complex datasets with non-linearities. However, conventional methods such as predictive mean matching work well for the Flatiron NSCLC biomarker dataset.

4 February 2026 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
MKMarija Kekic
Marija Kekic
OSOleg Stepanov
Oleg Stepanov
WWWenjuan Wang
Wenjuan Wang
SRSam Richardson
Sam Richardson
DODamilola Olabode
Damilola Olabode
ANAndrzej Nowojewski
Andrzej Nowojewski
Covariate selection in population pharmacokinetics modeling is essential for understanding interindividual variability in drug response and optimizing dosing. Traditional stepwise covariate modeling is often time‐consuming, compared to the new machine learning alternatives. This study investigates the use of neural networks with stochastic gates for automated covariate selection, aiming to efficiently identify relevant covariates while penalizing excessive covariate inclusion. On various synthetic datasets, the approach demonstrated robustness in detecting important covariates, overcoming challenges such as high correlations, low covariate frequencies, high interindividual variability, and complex covariate dependencies. In real clinical data from a monalizumab study, the method successfully identified covariates that matched those found by experts. However, for tixagevimab/cilgavimab, it identified a superset of covariates, indicating a potential need for further pruning. This machine learning‐based method enhances the covariate preselection process in population pharmacokinetics model development, offering significant time savings and improving efficiency even under challenging scenarios.

1 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MKMarija Kekic
Marija Kekic
OSOleg Stepanov
Oleg Stepanov
WWWenjuan Wang
Wenjuan Wang
SRSam Richardson
Sam Richardson
DODamilola Olabode
Damilola Olabode
ANAndrzej Nowojewski
Andrzej Nowojewski
Covariate selection in population pharmacokinetics modelling is essential for understanding interindividual variability in drug response and optimizing dosing. Traditional stepwise covariate modelling is often time-consuming, compared to the new machine learning alternatives. This study investigates the use of Neural Networks with Stochastic Gates for automated covariate selection, aiming to efficiently identify relevant covariates while penalizing excessive covariate inclusion. On various synthetic datasets the approach demonstrated robustness in detecting important covariates, overcoming challenges such as high correlations, low covariate frequencies, high interindividual variability and complex covariate dependencies. In real clinical data from a monalizumab study, the method successfully identified covariates that matched those found by experts. However, for tixagevimab/cilgavimab, it identified a superset of covariates, indicating a potential need for further pruning. This machine learning-based method enhances the covariate pre-selection process in population pharmacokinetics model development, offering significant time savings and improving efficiency even under challenging scenarios. WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?Covariate selection in population pharmacokinetics modelling is a crucial step in drug development and dosing determination. Traditionally, this process is conducted in a stepwise manner, which can be very time-consuming. Recently, fast machine learning (ML)-based methods for covariate selection have emerged in the literature, offering more efficient alternatives. WHAT QUESTION DID THIS STUDY ADDRESS?Can we use Neural Networks with Stochastic Gates, incorporating explicit penalization on the number of covariates, to select superior set of covariates compared to prior ML-based methods? WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?Neural Networks with Stochastic Gates provide a reliable approach in accurately detecting covariates because they can effectively eliminate irrelevant covariates even in cases with high inter-covariates correlation. HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?This approach accelerates pharmacokinetic model development by significantly reducing the time required for covariate evaluation. Additionally, it allows for the screening of a wider set of covariates, potentially leading to fewer falsely missed covariates and better-quality models, a task that would be infeasible with traditional stepwise covariate modelling.